Results 81 to 90 of about 354,756 (297)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2018
Oral anticoagulant therapy is recommended for the prevention and treatment of venous thromboembolism and to prevent stroke in non-valvular atrial fibrillation.
Maurizio Tala   +6 more
doaj   +1 more source

Anticoagulant-Related Nephropathy.

open access: yesJournal of the American Society of Nephrology, 2018
Anticoagulant-related nephropathy (ARN) is a newly recognized form of AKI in which overanticoagulation causes profuse glomerular hemorrhage, which manifests on renal biopsy as numerous renal tubules filled with red cells and red cell casts. The glomeruli
S. Brodsky, J. Eikelboom, L. Hebert
semanticscholar   +1 more source

Rupestonic Acid of Artemisia Rupestris L. Extract Treats Pulmonary Fibrosis in COPD by Targeting TGF‐β1

open access: yesAdvanced Science, EarlyView.
RA of EEAR inhibits TGF‐β1 ubiquitination and changes conformation by target binding TGF‐β1, regulating TGF‐β1/Smad2/3 signaling pathway. Thus it down‐regulated downstream protein expression, inhibited EMT and collagen deposition of ECM, in order to EEAR preventing PF in COPD.
Lingfeng Peng   +6 more
wiley   +1 more source

Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis

open access: yesAdvanced Science, EarlyView.
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen   +11 more
wiley   +1 more source

DABIGATRAN ETEXILATE IN ELDERL Y PATIENTS WITH ATRIAL FIBRILLATION: WHATS NEW?

open access: yesЕвразийский Кардиологический Журнал, 2017
The article discusses stroke prevention in elderly patients with atrial fibrillation. The principles of choosing anticoagulant therapy in this group of patients are discussed.
O. N. Tkacheva, N. M. Vorobyeva
doaj   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

open access: yesAdvanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin   +6 more
wiley   +1 more source

Multifunctional PLGA-based nanoparticles as a controlled release drug delivery system for antioxidant and anticoagulant therapy

open access: yesInternational Journal of Nanomedicine, 2019
Pei-Chi Lee,1 Bo-Shen Zan,1 Li-Ting Chen,1 Tze-Wen Chung1,2 1Department of Biomedical Engineering, National Yang Ming University, Taipei 112, Taiwan; 2Drug Delivery Department, Center for Advanced Pharmaceutics and Drug Delivery Research, National Yang ...
Lee PC, Zan BS, Chen LT, Chung TW
doaj  

Blood collection technique, anticoagulants and storing temperature have minor effects on the isolation of polymorphonuclear neutrophils [PDF]

open access: gold, 2020
Julia Krabbe   +7 more
openalex   +1 more source

Extracellular Vesicle‐Delivered tRF‐His‐GTG‐1 Reprograms Neutrophil Lipophagy and Triggers Inflammation in COVID‐19

open access: yesAdvanced Science, EarlyView.
This study identifies platelet‐derived extracellular vesicles as key immunometabolic regulators in COVID‐19. The delivery of tRF‐His‐GTG‐1 to neutrophils activates TLR8mTOR signaling, disrupts lipophagy, and amplifies NET‐mediated inflammation. Importantly, targeting this axis restores neutrophil homeostasis, offering a potential therapeutic strategy ...
Tsai‐Ling Liao   +5 more
wiley   +1 more source

Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants

open access: yesPLoS ONE, 2018
Objectives To quantify changes in anticoagulant use in Australia since the introduction of Non-vitamin K antagonist anticoagulants (NOACs) and to estimate government expenditure.
Alice Morgan   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy